Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
Brief Summary: This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether yeast derived sargramostim and vaccine therapy are more effective alone or together in preventing recurrence of melanoma.


Options:
A: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Elesclomol (STA-4783) | Arm Label: 2; Type: OTHER; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Elesclomol (STA-4783); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
C: Arm Label: Arm A: 2 courses ipi 3 + nivo 1; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Nivolumab, Procedure: Surgery, Procedure: Blood for PBMCs, Procedure: Biopsies | Arm Label: Arm B: 2 courses ipi 1 + nivo 3; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Nivolumab, Procedure: Surgery, Procedure: Blood for PBMCs, Procedure: Biopsies | Arm Label: Arm C: 2 courses ipi 3 + 2 courses nivo 3; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Nivolumab, Procedure: Surgery, Procedure: Blood for PBMCs, Procedure: Biopsies | Arm Label: PRADO extension cohort; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Nivolumab, Procedure: Surgery, Procedure: Blood for PBMCs, Procedure: Biopsies | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm A: 2 courses ipi 3 + nivo 1, Arm B: 2 courses ipi 1 + nivo 3, Arm C: 2 courses ipi 3 + 2 courses nivo 3, PRADO extension cohort | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: 2 courses ipi 3 + nivo 1, Arm B: 2 courses ipi 1 + nivo 3, Arm C: 2 courses ipi 3 + 2 courses nivo 3, PRADO extension cohort | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Arm A: 2 courses ipi 3 + nivo 1, Arm B: 2 courses ipi 1 + nivo 3, Arm C: 2 courses ipi 3 + 2 courses nivo 3, PRADO extension cohort | Intervention Type: PROCEDURE; Name: Blood for PBMCs; Assigned to Arm(s): Arm A: 2 courses ipi 3 + nivo 1, Arm B: 2 courses ipi 1 + nivo 3, Arm C: 2 courses ipi 3 + 2 courses nivo 3, PRADO extension cohort | Intervention Type: PROCEDURE; Name: Biopsies; Assigned to Arm(s): Arm A: 2 courses ipi 3 + nivo 1, Arm B: 2 courses ipi 1 + nivo 3, Arm C: 2 courses ipi 3 + 2 courses nivo 3, PRADO extension cohort
D: Arm Label: Arm I (sargramostim, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Biological: Tyrosinase Peptide | Arm Label: Arm II (sargramostim placebo, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Tyrosinase Peptide | Arm Label: Arm III (sargramostim, peptide placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Sargramostim | Arm Label: Arm IV (placebo, peptide placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Arm Label: Arm V (sargramostim); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim | Arm Label: Arm VI (sargramostim placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo), Arm V (sargramostim), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (sargramostim placebo, peptide vaccine), Arm IV (placebo, peptide placebo), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm V (sargramostim) | Intervention Type: BIOLOGICAL; Name: Tyrosinase Peptide; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine)

Answer: D